Clinical Commander

Back to dossier
neuro.spinal-cord-compression.v1PRODUCTION
neuro.spinal-cord-compression.v1

Metastatic Spinal Cord Compression (MSCC)

neurologyacutesubacuteadultgeriatric
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult cancer patient with new spine pain, motor deficit, sensory level, or sphincter dysfunction → suspect MSCC; time-critical oncologic emergency (Cole-Patchell Lancet Neurol 2008 PMID 18420159)

Inputs
0
Actions
0
Advance rule
Set
Advance when

MSCC suspected on clinical grounds; STAT MRI mobilised

Patient inputs (11)

Prior RT to same vertebral level → re-irradiation options limited; favours SBRT or surgery (Laufer J Neurosurg Spine 2013 PMID 23339593)

Age informs prognosis (Tokuhashi / Tomita scores) + treatment intensity (Loblaw 2012 PMID 22420969)

Radiosensitivity tiers drive RT-alone vs surgery-first decision (NOMS axis "O"; Laufer Oncologist 2013 PMID 23709750): radiosensitive = breast / prostate / myeloma / lymphoma / SCLC; radioresistant = NSCLC / RCC / melanoma / sarcoma / colorectal / hepatocellular

MRI whole spine is the diagnostic standard — multifocal disease in ≈30%; do NOT image only the symptomatic level (Loblaw 2012 PMID 22420969; NICE CG75)

CT for SINS bony stability assessment + RT planning + surgical planning (Fisher Spine 2010 PMID 20562730)

Pre-procedure baseline; CBC for marrow involvement; CMP for renal/electrolyte; coag for surgery/LP; LFT for bone-mets origin assessment

CRP/PCT/ESR — high in infection (spinal epidural abscess pivot); usually normal-modest in MSCC

Time-to-treatment is critical: <24-48 h motor deficit duration = ambulation salvage potential; >48 h = poor recovery (Loblaw 2012 PMID 22420969)

Strongest prognostic factor: ambulatory at presentation ≈80% retain ambulation post-Rx; non-ambulatory <24h ≈50% regain; non-ambulatory >24-48h <10% regain (Patchell Lancet 2005 PMID 16112300; Hoskin SCORAD JAMA 2019 PMID 31794625)

ECOG ≥3 OR Karnofsky <50 OR life-expectancy <3 mo → NOMS-S axis favours palliative RT (single-fraction 8 Gy per SCORAD) over surgery (Laufer Oncologist 2013 PMID 23709750; Hoskin SCORAD JAMA 2019 PMID 31794625)

NOMS "S" axis — visceral metastatic burden + treatment options remaining inform life-expectancy estimate (MacLean Lancet Oncol 2022 PMID 35772464)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (12)

12 need judgement
  • informationallife_threateningrapidly_progressive_motor_deficit
    New or worsening motor deficit (MRC drop ≥1 grade within hours-to-days) in cancer patient with back pain — emergent MSCC pivot (Loblaw 2012 PMID 22420969; Cole-Patchell PMID 18420159)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcauda_equina_syndrome_in_cancer_patient
    Saddle anesthesia + bilateral leg weakness + urinary retention / sphincter loss in cancer patient — STAT decompression within hours (NICE NG41)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcervical_level_compression
    Cervical spine MSCC with potential respiratory compromise — risk of diaphragmatic involvement at C3-C5; FVC + NIF monitoring; ICU watch (Cole-Patchell PMID 18420159)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdifferential_spinal_epidural_abscess_pivot
    Fever + IVDU + CRP >100 + risk factors for bacteraemia / endocarditis + epidural enhancement on MRI — pivot to id.spinal-epidural-abscess.v1 (NOT MSCC)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresensory_level_or_complete_cord_syndrome
    Definable sensory level on trunk OR complete motor + sensory + autonomic loss below a spinal level — late + ominous finding (Cole-Patchell PMID 18420159)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremechanical_instability_sins_high
    SINS ≥7 (Fisher Spine 2010 PMID 20562730) — pain on movement, kyphosis, posterior-element involvement, vertebral-body collapse >50% → mechanical instability axis of NOMS (Laufer Oncologist 2013 PMID 23709750); calc.sins is schema-blocked
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereradioresistant_tumour_with_compressive_disease
    NSCLC / RCC / melanoma / sarcoma / colorectal / hepatocellular primary with epidural compression — radioresistant tumour (NOMS-O axis); separation surgery + SBRT preferred over conventional RT alone (Laufer J Neurosurg Spine 2013 PMID 23339593)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremultifocal_spinal_disease_30pct
    MRI shows compression at >1 vertebral level (≈30% of MSCC presentations) — never image only the symptomatic level (Loblaw 2012 PMID 22420969; NICE CG75)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereunknown_primary_with_mscc
    MSCC as initial cancer presentation — biopsy of accessible site (vertebral or other) for histology; restaging CT/PET; treat empirically with steroid + RT while histology pending (Loblaw 2012 PMID 22420969)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereprior_RT_to_same_level
    Patient has received prior conventional RT to the same vertebral level — re-irradiation tolerance limited; favours SBRT / separation surgery + SBRT (Laufer J Neurosurg Spine 2013 PMID 23339593)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateshort_life_expectancy_palliative_RT_pathway
    Life-expectancy <3 mo (poor ECOG, extensive visceral disease, treatment-refractory) — favours 8 Gy single-fraction palliative RT (Hoskin SCORAD JAMA 2019 PMID 31794625; Maranzano JCO 2005 PMID 15738534)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateosteoporotic_vertebral_compression_fracture_differential
    Vertebral collapse without epidural soft-tissue / without cord signs / postmenopausal / glucocorticoid-induced — osteoporotic VCF (NOT MSCC); kyphoplasty/vertebroplasty may be appropriate (NICE NG41)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

FOLLOWUPoptionalDrives screening
Loading…

Recommended regimen

MSCC acute care bundle — dexamethasone + RT/surgery + anti-resorptive + analgesia (Loblaw 2012 PMID 22420969; Patchell Lancet 2005 PMID 16112300; Hoskin SCORAD JAMA 2019 PMID 31794625; Sørensen Eur J Cancer 1994 PMID 8142159)
axis: mscc_acute_bundlestep 1 - Step 1 — Dexamethasone IMMEDIATELY on clinical suspicion (do NOT wait for MRI; Loblaw 2012 PMID 22420969)
Selected step "Step 1 — Dexamethasone IMMEDIATELY on clinical suspicion (do NOT wait for MRI; Loblaw 2012 PMID 22420969)" — Any cancer patient with new motor / sensory level / sphincter deficit + suspicion of MSCC
  • dexamethasone (high-dose, severe deficit)
    first line
    corticosteroid_pulse
    96 mg IV bolus, then 96 mg PO daily × 3 days, then taper over 10 days • IV→PO • bolus then daily taper
    triggers: severe_motor_deficit, paraplegia_or_severe_paresis
    Sørensen Eur J Cancer 1994 (PMID 8142159) — high-dose dexamethasone improves 6-mo ambulation 59% vs 33% in severe deficit; PPI cover; glucose watch
    rxcui 3264
  • dexamethasone (standard-dose, mild-moderate deficit)
    first line
    corticosteroid
    10 mg IV bolus, then 16 mg/day in divided doses (4 mg q6h or 8 mg q12h) for 48-72 h, then taper over 1-2 wk concurrent with RT • IV→PO • q6-12h taper
    triggers: mild_to_moderate_motor_deficit, ambulatory_or_minimally_symptomatic
    Loblaw 2012 PMID 22420969 — standard-dose taper avoids high-dose toxicity (peptic ulcer, GI bleed, hyperglycaemia, mood) while preserving benefit
    rxcui 3264

outpatient playbook — drug actions (6)

  1. 1. dexamethasone OFF (taper complete)
    Discontinued after RT • n/a • n/a
    trigger: Post-RT completion
    Avoid chronic steroid
  2. 2. denosumab OR zoledronic acid
    Denosumab 120 mg SC q4w; zoledronic 4 mg IV q3-4w • SC/IV • q3-4w
    trigger: Polyostotic disease
    Long-term anti-resorptive
  3. 3. morphine / oxycodone (titrated)
    Long-acting + breakthrough; taper as pain allows • PO • q8-12h + PRN
    trigger: Ongoing pain
    WHO step 3 maintained while indicated
  4. 4. gabapentinoid
    Continue or taper based on neuropathic-pain trajectory • PO • BID/TID
    trigger: Neuropathic pain
    Continue if effective
  5. 5. calcium 1000-1200 mg/d + vitamin D 800-1000 IU/d
    Per supplement • PO • daily
    trigger: On anti-resorptive
    Mandatory supplementation with anti-resorptive
  6. 6. sertraline OR escitalopram (PRN for PHQ-9 ≥10)
    Sertraline 50 mg PO daily; escitalopram 10 mg PO daily • PO • daily
    trigger: PHQ-9 ≥10
    Post-MSCC depression first-line SSRI

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New / worsening back pain in a cancer patient — presenting symptom in ≈95% of MSCC (Cole-Patchell Lancet Neurol 2008 PMID 18420159); often nocturnal + worsens recumbent + worsens with Valsalva; New motor weakness in cancer patient — second most common feature after back pain (Loblaw 2012 PMID 22420969); Sensory level on trunk or saddle anesthesia — late finding; localizes spinal level (Patchell Lancet 2005 PMID 16112300).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Metastatic Spinal Cord Compression (MSCC)** (neuro.spinal-cord-compression.v1).
Phenotype framing: Phenotype — radiosensitive (breast / prostate / myeloma / lymphoma / SCLC) vs radioresistant (NSCLC / RCC / melanoma / sarcoma / colorectal / hepatocellular); polyostotic vs isolated; mechanical-instability axis (SINS); life-expectancy axis (>3 mo vs <3 mo; Tokuhashi schema-blocked). DDx: spinal epidural abscess (id pivot — fever + CRP↑↑↑), epidural hematoma, traumatic compression, transverse myelitis, osteoporotic compression fracture, discitis-osteomyelitis (Cole-Patchell PMID 18420159; MacLean Lancet Oncol 2022 PMID 35772464)
Scope: Adult cancer patient with new spine pain, motor deficit, sensory level, or sphincter dysfunction → suspect MSCC; time-critical oncologic emergency (Cole-Patchell Lancet Neurol 2008 PMID 18420159)

No severity triggers fired against current inputs.

Plan

Regimen axis: **MSCC acute care bundle — dexamethasone + RT/surgery + anti-resorptive + analgesia (Loblaw 2012 PMID 22420969; Patchell Lancet 2005 PMID 16112300; Hoskin SCORAD JAMA 2019 PMID 31794625; Sørensen Eur J Cancer 1994 PMID 8142159)** — step "Step 1 — Dexamethasone IMMEDIATELY on clinical suspicion (do NOT wait for MRI; Loblaw 2012 PMID 22420969)".
1. dexamethasone (high-dose, severe deficit) 96 mg IV bolus, then 96 mg PO daily × 3 days, then taper over 10 days IV→PO bolus then daily taper (corticosteroid_pulse, first line) — Sørensen Eur J Cancer 1994 (PMID 8142159) — high-dose dexamethasone improves 6-mo ambulation 59% vs 33% in severe deficit; PPI cover; glucose watch
2. dexamethasone (standard-dose, mild-moderate deficit) 10 mg IV bolus, then 16 mg/day in divided doses (4 mg q6h or 8 mg q12h) for 48-72 h, then taper over 1-2 wk concurrent with RT IV→PO q6-12h taper (corticosteroid, first line) — Loblaw 2012 PMID 22420969 — standard-dose taper avoids high-dose toxicity (peptic ulcer, GI bleed, hyperglycaemia, mood) while preserving benefit

Setting playbook (outpatient) — Outpatient surveillance + RT completion + rehab + anti-resorptive + cancer-survivorship clinic; PHQ-9; recurrence-symptom education; advance-care planning (Loblaw 2012 PMID 22420969; NICE NG41)
3. dexamethasone OFF (taper complete) Discontinued after RT n/a n/a — Post-RT completion (Avoid chronic steroid)
4. denosumab OR zoledronic acid Denosumab 120 mg SC q4w; zoledronic 4 mg IV q3-4w SC/IV q3-4w — Polyostotic disease (Long-term anti-resorptive)
5. morphine / oxycodone (titrated) Long-acting + breakthrough; taper as pain allows PO q8-12h + PRN — Ongoing pain (WHO step 3 maintained while indicated)
6. gabapentinoid Continue or taper based on neuropathic-pain trajectory PO BID/TID — Neuropathic pain (Continue if effective)
7. calcium 1000-1200 mg/d + vitamin D 800-1000 IU/d Per supplement PO daily — On anti-resorptive (Mandatory supplementation with anti-resorptive)
8. sertraline OR escitalopram (PRN for PHQ-9 ≥10) Sertraline 50 mg PO daily; escitalopram 10 mg PO daily PO daily — PHQ-9 ≥10 (Post-MSCC depression first-line SSRI)

Non-pharmacologic actions:
- Outpatient PT/OT continuation
- Cancer survivorship clinic
- Palliative-care continuity
- Recurrence-symptom education at every visit
- Bowel + bladder management
- Pressure-area care + skin checks
- Driving evaluation + return-to-work / leisure assessment
- Caregiver support + respite
- ACP / POLST / DNACPR review
- Smoking + alcohol cessation reinforcement

AVOID / contraindication checks:
- Dexamethasone_with_PPI_cover_during_high_dose (Loblaw 2012 PMID 22420969)
- Dexamethasone_glucose_monitoring_q6h (Sørensen Eur J Cancer 1994 PMID 8142159)
- No_routine_platelet_transfusion_for_antiplatelet_use_in_MSCC
- No_VTE_pharmacoprophylaxis_until_24 48h_post_decompression_surgery
- Denosumab_calcium_vitamin_D_supplementation_mandatory_ONJ_risk_hold_pre_dental
- Zoledronic_acid_avoid_CrCl_<30_ONJ_risk_calcium_vitamin_D
- Opioid_constipation_prophylaxis_senna_macrogol_mandatory
- Morphine_renal_adjust_or_switch_to_oxycodone_or_fentanyl_if_CrCl_<30
- Gabapentinoid_renal_adjust_CrCl_titration
- No_kyphoplasty_or_vertebroplasty_routinely_for_neoplastic_compression_with_cord_signs (NICE NG41 — different from osteoporotic VCF)
- NEVER_image_only_symptomatic_level_multifocal_disease_30pct (Loblaw 2012 PMID 22420969)
- NEVER_delay_dexamethasone_for_imaging_first_dose_at_clinical_suspicion (Loblaw 2012 PMID 22420969)

Monitoring

Regimen monitoring:
- Daily neuro exam (motor power MRC, sensory level, sphincter, perianal sensation) × inpatient stay
- Ambulatory-status documentation at presentation + post-treatment day 1 / 7 / 28 / 8 wk
- Glucose q6h during high-dose dexamethasone (Sørensen Eur J Cancer 1994 PMID 8142159)
- CBC + CMP + LFT weekly during admission
- Pain score (numeric 0-10) q4h with opioid titration
- Bowel + bladder function daily; bladder scan if retention suspected
- Calcium + vitamin D + renal function q3 mo during anti-resorptive therapy
- Repeat MRI at 3 mo + as clinically indicated (Loblaw 2012 PMID 22420969)
- PHQ-9 at 4-8 wk + 3 mo + 6 mo (post-MSCC depression frequent)

Setting (outpatient) monitoring:
- 4-8 wk + 3 mo + 6 mo + 12 mo clinic visits
- MRI at 3 mo + as clinically indicated
- CBC + BMP + calcium + creatinine + LFT q3 mo
- PHQ-9 at 4-8 wk + 3 mo + 6 mo
- Anti-resorptive every 3-4 wk
- Restaging per primary tumour
- Dental review q6 mo

Follow-up plan: Outpatient oncology + radiation oncology + neurosurgery (if operated) + rehab; PHQ-9 depression screen (post-MSCC depression high); bowel/bladder management; recurrence-symptom education; anti-resorptive therapy ongoing; advance-care-planning discussion (life-expectancy is the dominant prognostic factor)
- Close-out criterion: Long-term plan + specialty referrals + ACP scheduled

Monitoring phase: Daily neuro exam + ambulation + sensory level + sphincter function during admission; pain score; steroid side-effects (glucose, gastric, mood, sleep); bone-mineral burden; secondary VTE prophylaxis (LMWH 24-48 h post-decompression). Repeat MRI at 3 mo + as clinically indicated (Loblaw 2012 PMID 22420969)

Disposition

Current setting: outpatient — Outpatient surveillance + RT completion + rehab + anti-resorptive + cancer-survivorship clinic; PHQ-9; recurrence-symptom education; advance-care planning (Loblaw 2012 PMID 22420969; NICE NG41)

Disposition criteria:
- Continue long-term cancer survivorship + anti-resorptive + palliative care
- Transition to hospice if disease-trajectory shifts to palliative-only

Escalation triggers (move to higher acuity):
- Recurrent / new back pain → STAT MRI
- Any new neurological deficit → ED + STAT MRI
- New bone-pain elsewhere → restaging
- PHQ-9 ≥15 OR suicidal ideation → psych urgent
- Hypercalcaemia symptoms → ED
- ONJ symptoms → dental + hold anti-resorptive

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] New or worsening motor deficit (MRC drop ≥1 grade within hours-to-days) in cancer patient with back pain — emergent MSCC pivot (Loblaw 2012 PMID 22420969; Cole-Patchell PMID 18420159)
- [LIFE_THREATENING] Saddle anesthesia + bilateral leg weakness + urinary retention / sphincter loss in cancer patient — STAT decompression within hours (NICE NG41)
- [LIFE_THREATENING] Cervical spine MSCC with potential respiratory compromise — risk of diaphragmatic involvement at C3-C5; FVC + NIF monitoring; ICU watch (Cole-Patchell PMID 18420159)

Citations

- Loblaw IJROBP 2012 Cancer Care Ontario MESCC practice guideline (PMID 22420969) + NICE NG41 metastatic spinal cord compression + Patchell Lancet 2005 surgery RCT (PMID 16112300) + Hoskin SCORAD JAMA 2019 (PMID 31794625) + Laufer NOMS Oncologist 2013 (PMID 23709750) [PMID:22420969](https://pubmed.ncbi.nlm.nih.gov/22420969/)
- Cited evidence (PMID 16112300) [PMID:16112300](https://pubmed.ncbi.nlm.nih.gov/16112300/)
- Cited evidence (PMID 31794625) [PMID:31794625](https://pubmed.ncbi.nlm.nih.gov/31794625/)
- Cited evidence (PMID 35618101) [PMID:35618101](https://pubmed.ncbi.nlm.nih.gov/35618101/)
- Cited evidence (PMID 15738534) [PMID:15738534](https://pubmed.ncbi.nlm.nih.gov/15738534/)

Last reconciled with current guidelines: 2026-05-26.
References
  • Loblaw IJROBP 2012 Cancer Care Ontario MESCC practice guideline (PMID 22420969) + NICE NG41 metastatic spinal cord compression + Patchell Lancet 2005 surgery RCT (PMID 16112300) + Hoskin SCORAD JAMA 2019 (PMID 31794625) + Laufer NOMS Oncologist 2013 (PMID 23709750) — PMID:22420969
  • Cited evidence (PMID 16112300) — PMID:16112300
  • Cited evidence (PMID 31794625) — PMID:31794625
  • Cited evidence (PMID 35618101) — PMID:35618101
  • Cited evidence (PMID 15738534) — PMID:15738534